News Related to Generate Biomedicines

Related coverage linked through entity extraction aliases.

CAR-T Therapy Firms Announce Manufacturing Expansion and Investment Activity

Jun 01, 2026

CARsgen Therapeutics has signed a RMB370 million agreement to build a CAR T-cell manufacturing base in Shanghai, supporting commercialization of its marketed and late-stage products. Meanwhile, investment firm HarbourVest disclosed a $21 million position in CAR-T developer Generate Biomedicines, which holds $516.6 million in cash after its IPO.

FDA Streamlines Drug Approvals, Offers Reviewer Bonuses Under New Policies

Mar 20, 2026

The FDA announced major policy changes including requiring only one study for drug approvals instead of two, and offering performance bonuses to reviewers who complete work ahead of schedule while maintaining thoroughness.